Drug intelligence / Profile preview

ABBV-453 + dexamethasone

Development stage: Unknown
Lead developer: AbbVie
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

ABBV-453 + dexamethasone is a combination regimen under investigation for the treatment of relapsed or refractory multiple myeloma. ABBV-453 is an **oral small molecule inhibitor of BCL-2**, developed to induce apoptosis in myeloma plasma cells with high BCL-2 expression or t(11;14) translocation, a common genetic feature in multiple myeloma[1][3][5][7]. **Dexamethasone** is a synthetic glucocorticoid corticosteroid that exerts antineoplastic activity by suppressing inflammation and inducing tumor cell apoptosis. Together, these agents are being evaluated in phase 1/2 trials for synergistic effects.

Targets

GR (Glucocorticoid receptor)BCL-2 (BCL-2 family)

Beyond the preview

Go deeper on ABBV-453 + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-453 + dexamethasone.

Explore the full profile